Table of Contents
Chemotherapy Research and Practice
Volume 2013 (2013), Article ID 726925, 7 pages
http://dx.doi.org/10.1155/2013/726925
Clinical Study

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases

1Department of Dermatology, Anheuser-Busch Institute, Saint Louis University, 1402 S. Grand Boulevard., 4th Floor, St. Louis, MO 63104, USA
2Division of Hematology and Oncology, Saint Louis University, 3655 Vista Avenue, 3rd Floor, St. Louis, MO 63110, USA
3Center for Outcomes Research, Saint Louis University, 3545 Lafayette Avenue, 4th Floor, St. Louis, MO 63104, USA
4Division of General Surgery, Saint Louis University, 3655 Vista Avenue, St. Louis, MO 63110, USA

Received 26 February 2013; Revised 20 April 2013; Accepted 22 April 2013

Academic Editor: Vassilios A. Georgoulias

Copyright © 2013 Melinda B. Chu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Melinda B. Chu, Mark J. Fesler, Eric S. Armbrecht, Scott W. Fosko, Eddy Hsueh, and John M. Richart, “High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases,” Chemotherapy Research and Practice, vol. 2013, Article ID 726925, 7 pages, 2013. doi:10.1155/2013/726925